Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Economic Burden of Schizophrenia in the United States: A National Level Analysis

Speaker(s)

Zaki S1, Agrawal N2, Paul R2, Kathe N2, Aparasu R3
1Complete HEOR Solutions (CHEORS), VADODARA, GJ, India, 2Complete HEOR Solutions (CHEORS), North Wales, PA, USA, 3University of Houston, Houston, TX, USA

Presentation Documents

OBJECTIVES: Schizophrenia is associated with considerable disability and a high healthcare burden. This study evaluated marginal healthcare expenditure among schizophrenia patients in the US using the Medical Expenditure Panel Survey (MEPS).

METHODS: A cross-sectional study was conducted using the 2012-2019 MEPS, a nationally representative survey of noninstitutionalized individuals in the US. The study sample included (≥ 18 years), with (using ICD-9-CM codes: 295.xx and 298.xx, and ICD-10-CM code: F20.xx). The annual health expenditures involving various healthcare components were compared for patients with and without schizophrenia. Generalized Linear Model (GLM) with gamma distribution, log link, and Inverse Probability of Treatment Weighting (IPTW) was employed to compare the annual healthcare expenditures among the study groups.

RESULTS: The study identified 463 patients, representing 0.47 million schizophrenia patients in the US with an overall prevalence of 1.82%. Most of these patients were 18-34 years old (31.62%), male (59%), non-Hispanic whites (66%), never married (50%), non-smokers (58%), and belonged to the low-income category (67%). The mean Charlson Comorbidity Index (CCI) score was 0.79 (SE=0.07). The total annualized expenditure among the schizophrenia cohort was estimated to be $9.23 billion. The adjusted annual mean total costs among patients with schizophrenia ($19,539 [SE=$1,592]) were significantly higher than those without schizophrenia ($9,925 [SE=$ 179]) with incidence rate ratio (IRR) of 1.97 (95% CI:(1.68,2.31); p-value < 0.001). Prescribed medicines were the largest drivers of the total annual expenditures among patients with schizophrenia (Mean: $6,580 [SE=$551]) compared to non- schizophrenia patients (Mean: $2,816 [SE=$76]).

CONCLUSIONS: This study highlighted a considerable economic burden among patients with schizophrenia, especially prescription costs. Given the high prescription burden, future therapeutic approaches are needed to address the economic burden of schizophrenia.

Code

RWD24

Topic

Real World Data & Information Systems

Topic Subcategory

Reproducibility & Replicability

Disease

Neurological Disorders, No Additional Disease & Conditions/Specialized Treatment Areas